Cargando…

Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea

OBJECTIVES: The aim of this study was to evaluate the patient’s perception of the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) and provide a basis for physicians to understand the patient’s perspective. PATIENTS AND METHODS: Between December 2018 and June 2019, a total of 307 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, In Ah, Kim, Ji Hyoun, Hae Chang, Sung, Song, Ran, Ha, You-Jung, Won Kim, Hye, Seok Lee, Jeong, Choi, Byoongyong, Oh, Yoon-Jeong, Moon, Ki Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish League Against Rheumatism 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957778/
https://www.ncbi.nlm.nih.gov/pubmed/35382362
http://dx.doi.org/10.46497/ArchRheumatol.2021.8524
_version_ 1784676804733173760
author Choi, In Ah
Kim, Ji Hyoun
Hae Chang, Sung
Song, Ran
Ha, You-Jung
Won Kim, Hye
Seok Lee, Jeong
Choi, Byoongyong
Oh, Yoon-Jeong
Moon, Ki Won
author_facet Choi, In Ah
Kim, Ji Hyoun
Hae Chang, Sung
Song, Ran
Ha, You-Jung
Won Kim, Hye
Seok Lee, Jeong
Choi, Byoongyong
Oh, Yoon-Jeong
Moon, Ki Won
author_sort Choi, In Ah
collection PubMed
description OBJECTIVES: The aim of this study was to evaluate the patient’s perception of the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) and provide a basis for physicians to understand the patient’s perspective. PATIENTS AND METHODS: Between December 2018 and June 2019, a total of 307 patients (162 males, 145 females; mean age: 48 years; range, 18 to 81 years) were included in this investigator-initiated, multi-center, observational, and cross-sectional study in six rheumatology centers. We asked patients using bDMARDs to treat rheumatoid arthritis (RA) or ankylosing spondylitis (AS) to complete a questionnaire regarding major considerations and satisfaction with bDMARDs, preferred administration route, knowledge about bDMARDs, experiences of adverse events, non-adherence, and expectations of their healthcare provider. The satisfaction of physician and clinical information on the patient's disease and treatment were also collected. RESULTS: Of the patients, 139 had RA and 168 had AS. Median disease duration was six years in RA and five years in AS. A total of 80.1% of the patients and 77.1% of the physicians indicated being satisfied or very satisfied with the therapeutic effect of the current bDMARD. Most patients were open to intravenous or subcutaneous injection, with the most preferred route of administration being subcutaneous (41.3%), followed by intravenous (32.0%), and oral (26.7%). The patients considered therapeutic effect to be more important than cost or convenience while choosing a bDMARD (69.3%), and most were willing to be educated about therapeutic effects (46.1%). Only 35.2% of the patients reported well and/or very well knowledge about the therapeutic effects, side effects, and administration methods of their current bDMARD, and 86.6% cited their physician as the primary source of information about biological treatment. CONCLUSION: Patients value therapeutic effect more than cost or convenience while selecting a bDMARD, and consider their physicians to be the primary information source. Therefore, it is important for physicians to provide appropriate education and encourage patients to cooperate actively with treatment.
format Online
Article
Text
id pubmed-8957778
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Turkish League Against Rheumatism
record_format MEDLINE/PubMed
spelling pubmed-89577782022-04-04 Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea Choi, In Ah Kim, Ji Hyoun Hae Chang, Sung Song, Ran Ha, You-Jung Won Kim, Hye Seok Lee, Jeong Choi, Byoongyong Oh, Yoon-Jeong Moon, Ki Won Arch Rheumatol Original Article OBJECTIVES: The aim of this study was to evaluate the patient’s perception of the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) and provide a basis for physicians to understand the patient’s perspective. PATIENTS AND METHODS: Between December 2018 and June 2019, a total of 307 patients (162 males, 145 females; mean age: 48 years; range, 18 to 81 years) were included in this investigator-initiated, multi-center, observational, and cross-sectional study in six rheumatology centers. We asked patients using bDMARDs to treat rheumatoid arthritis (RA) or ankylosing spondylitis (AS) to complete a questionnaire regarding major considerations and satisfaction with bDMARDs, preferred administration route, knowledge about bDMARDs, experiences of adverse events, non-adherence, and expectations of their healthcare provider. The satisfaction of physician and clinical information on the patient's disease and treatment were also collected. RESULTS: Of the patients, 139 had RA and 168 had AS. Median disease duration was six years in RA and five years in AS. A total of 80.1% of the patients and 77.1% of the physicians indicated being satisfied or very satisfied with the therapeutic effect of the current bDMARD. Most patients were open to intravenous or subcutaneous injection, with the most preferred route of administration being subcutaneous (41.3%), followed by intravenous (32.0%), and oral (26.7%). The patients considered therapeutic effect to be more important than cost or convenience while choosing a bDMARD (69.3%), and most were willing to be educated about therapeutic effects (46.1%). Only 35.2% of the patients reported well and/or very well knowledge about the therapeutic effects, side effects, and administration methods of their current bDMARD, and 86.6% cited their physician as the primary source of information about biological treatment. CONCLUSION: Patients value therapeutic effect more than cost or convenience while selecting a bDMARD, and consider their physicians to be the primary information source. Therefore, it is important for physicians to provide appropriate education and encourage patients to cooperate actively with treatment. Turkish League Against Rheumatism 2021-06-24 /pmc/articles/PMC8957778/ /pubmed/35382362 http://dx.doi.org/10.46497/ArchRheumatol.2021.8524 Text en Copyright © 2021, Turkish League Against Rheumatism https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Article
Choi, In Ah
Kim, Ji Hyoun
Hae Chang, Sung
Song, Ran
Ha, You-Jung
Won Kim, Hye
Seok Lee, Jeong
Choi, Byoongyong
Oh, Yoon-Jeong
Moon, Ki Won
Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea
title Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea
title_full Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea
title_fullStr Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea
title_full_unstemmed Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea
title_short Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea
title_sort patient perspectives on biological treatments for inflammatory arthritis: a multi-center study in korea
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957778/
https://www.ncbi.nlm.nih.gov/pubmed/35382362
http://dx.doi.org/10.46497/ArchRheumatol.2021.8524
work_keys_str_mv AT choiinah patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT kimjihyoun patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT haechangsung patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT songran patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT hayoujung patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT wonkimhye patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT seokleejeong patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT choibyoongyong patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT ohyoonjeong patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea
AT moonkiwon patientperspectivesonbiologicaltreatmentsforinflammatoryarthritisamulticenterstudyinkorea